Compare Stocks: ABSI, DYN, CRSP, and ACAD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.93 +7.6%	$8.57	$2.24 ▼ $12.06	$1.29B	2.35	3.06 million shs	2.19 million shs
ACAD ACADIA Pharmaceuticals	$29.21 +2.7%	$24.39	$19.69 ▼ $29.48	$4.90B	0.81	1.68 million shs	1.78 million shs
CRSP CRISPR Therapeutics	$53.52 +3.6%	$52.37	$44.12 ▼ $78.48	$4.99B	1.74	1.66 million shs	1.28 million shs
DYN Dyne Therapeutics	$26.25 +1.4%	$22.00	$10.78 ▼ $27.09	$4.83B	1.07	2.64 million shs	1.99 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+7.59%	+14.78%	-19.55%	+51.36%	+207.40%
ACAD ACADIA Pharmaceuticals	+2.67%	+12.91%	+12.35%	+30.40%	+22.73%
CRSP CRISPR Therapeutics	+3.64%	+11.52%	-9.59%	-2.39%	-5.01%
DYN Dyne Therapeutics	+1.43%	+4.25%	+10.16%	+49.06%	+126.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.93 +7.6%	$8.57	$2.24 ▼ $12.06	$1.29B	2.35	3.06 million shs	2.19 million shs
ACAD ACADIA Pharmaceuticals	$29.21 +2.7%	$24.39	$19.69 ▼ $29.48	$4.90B	0.81	1.68 million shs	1.78 million shs
CRSP CRISPR Therapeutics	$53.52 +3.6%	$52.37	$44.12 ▼ $78.48	$4.99B	1.74	1.66 million shs	1.28 million shs
DYN Dyne Therapeutics	$26.25 +1.4%	$22.00	$10.78 ▼ $27.09	$4.83B	1.07	2.64 million shs	1.99 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+7.59%	+14.78%	-19.55%	+51.36%	+207.40%
ACAD ACADIA Pharmaceuticals	+2.67%	+12.91%	+12.35%	+30.40%	+22.73%
CRSP CRISPR Therapeutics	+3.64%	+11.52%	-9.59%	-2.39%	-5.01%
DYN Dyne Therapeutics	+1.43%	+4.25%	+10.16%	+49.06%	+126.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.78	Moderate Buy	$13.43	50.38% Upside
ACAD ACADIA Pharmaceuticals	2.82	Moderate Buy	$33.44	14.49% Upside
CRSP CRISPR Therapeutics	2.58	Moderate Buy	$68.06	27.16% Upside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.42	31.11% Upside

Current Analyst Ratings Breakdown

Latest ABSI, DYN, CRSP, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	CRSP CRISPR Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$55.00
8/6/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $37.00
8/5/2026	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$23.00 ➝ $25.00
8/5/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	ACAD ACADIA Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$35.00 ➝ $36.00
8/4/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $88.00
7/31/2026	DYN Dyne Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$47.00 ➝ $45.00
7/30/2026	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $35.00
7/29/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/29/2026	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.50

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	497.21	N/A	N/A	$1.26 per share	7.09
ACAD ACADIA Pharmaceuticals	$1.07B	4.70	$0.91 per share	32.07	$7.58 per share	3.85
CRSP CRISPR Therapeutics	$3.51M	1,474.32	N/A	N/A	$18.06 per share	2.96
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$3.76 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.83	N/A	N/A	N/A	-6,450.76%	-66.32%	-57.01%	8/11/2026 (Estimated)
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.16	28.92	16.74	33.42%	9.03%	6.79%	N/A
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	8/10/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	N/A

Latest ABSI, DYN, CRSP, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ABSI Absci	-$0.15	N/A	N/A	N/A	$0.89 million	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million
5/11/2026	Q1 2026	DYN Dyne Therapeutics	-$0.7723	-$0.73	+$0.0423	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	6.59	6.59
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.48
CRSP CRISPR Therapeutics	0.34	17.85	17.96
DYN Dyne Therapeutics	0.28	12.02	12.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
ACAD ACADIA Pharmaceuticals	96.71%
CRSP CRISPR Therapeutics	69.20%
DYN Dyne Therapeutics	96.68%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
ACAD ACADIA Pharmaceuticals	26.20%
CRSP CRISPR Therapeutics	5.20%
DYN Dyne Therapeutics	9.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	210	155.90 million	139.50 million	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	126.37 million	Optionable
CRSP CRISPR Therapeutics	460	96.69 million	91.67 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable

ABSI, DYN, CRSP, and ACAD Headlines

Recent News About These Companies

Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN

August 8 at 3:43 AM | marketbeat.com

Raymond James Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

August 6 at 9:08 PM | theglobeandmail.com

Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week High - Should You Buy?

August 5 at 11:59 AM | marketbeat.com

Bank of New York Mellon Corp Buys 48,119 Shares of Dyne Therapeutics, Inc. $DYN

August 4, 2026 | marketbeat.com

Dyne Therapeutics, Inc. $DYN Shares Purchased by Renaissance Technologies LLC

August 3, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Illumina (ILMN), Dyne Therapeutics (DYN) and Bristol-Myers Squibb (BMY)

August 2, 2026 | theglobeandmail.com

Dyne Therapeutics, Inc. $DYN Shares Purchased by Perceptive Advisors LLC

August 2, 2026 | marketbeat.com

Dyne Therapeutics (NASDAQ:DYN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

August 1, 2026 | americanbankingnews.com

Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen

August 1, 2026 | americanbankingnews.com

Dyne Therapeutics (NASDAQ:DYN) Cut to Strong Sell at Wall Street Zen

August 1, 2026 | marketbeat.com

Piper Sandler Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

July 31, 2026 | theglobeandmail.com

Dyne Therapeutics, Inc. $DYN Shares Sold by Vivo Capital LLC

July 31, 2026 | marketbeat.com

Janus Henderson Group PLC Sells 240,346 Shares of Dyne Therapeutics, Inc. $DYN

July 31, 2026 | marketbeat.com

Dyne Therapeutics (NASDAQ:DYN) Given New $35.00 Price Target at Royal Bank Of Canada

July 30, 2026 | marketbeat.com

Stempoint Capital LP Sells 329,125 Shares of Dyne Therapeutics, Inc. $DYN

July 30, 2026 | marketbeat.com

Dyne Therapeutics (NASDAQ:DYN) Releases Earnings Results, Misses Expectations By $0.34 EPS

July 29, 2026 | marketbeat.com

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

July 29, 2026 | globenewswire.com

Dyne Therapeutics Receives FDA Clearance to Start Trial of Muscle Disease Treatment

July 28, 2026 | finance.yahoo.com

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

July 28, 2026 | globenewswire.com

Rock Springs Capital Management LP Has $17.63 Million Stake in Dyne Therapeutics, Inc. $DYN

July 28, 2026 | marketbeat.com

SummitTX Capital L.P. Cuts Position in Dyne Therapeutics, Inc. $DYN

July 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABSI, DYN, CRSP, and ACAD Company Descriptions

Absci NASDAQ:ABSI

$8.93 +0.63 (+7.59%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$8.94 +0.01 (+0.12%)

As of 08/7/2026 07:49 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.21 +0.76 (+2.67%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$28.86 -0.36 (-1.22%)

As of 08/7/2026 07:59 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

CRISPR Therapeutics NASDAQ:CRSP

$53.52 +1.88 (+3.64%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$53.63 +0.11 (+0.21%)

As of 08/7/2026 07:48 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Dyne Therapeutics NASDAQ:DYN

$26.25 +0.37 (+1.43%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$26.08 -0.17 (-0.65%)

As of 08/7/2026 07:34 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABSI, DYN, CRSP, and ACAD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABSI, DYN, CRSP, and ACAD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABSI, DYN, CRSP, and ACAD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABSI, DYN, CRSP, and ACAD Company Descriptions

Absci NASDAQ:ABSI

ACADIA Pharmaceuticals NASDAQ:ACAD

CRISPR Therapeutics NASDAQ:CRSP

Dyne Therapeutics NASDAQ:DYN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABSI, DYN, CRSP, and ACAD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABSI, DYN, CRSP, and ACAD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABSI, DYN, CRSP, and ACAD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABSI, DYN, CRSP, and ACAD Company Descriptions

Absci NASDAQ:ABSI

ACADIA Pharmaceuticals NASDAQ:ACAD

CRISPR Therapeutics NASDAQ:CRSP

Dyne Therapeutics NASDAQ:DYN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools